ESMO 2024: Priority Report: Updates in Renal Cell Carcinoma

home / publications / supplements / esmo-2024-priority-report-updates-in-renal-cell-carcinoma
Eric Jonasch, MD, of MD Anderson Cancer Center

NKT2152 Data Reinforce the Importance of HIF2α Inhibition in Advanced Clear Cell RCC

Caroline Seymour
September 19th 2024
Article

The novel oral HIF2α inhibitor NKT2152 elicited encouraging responses in patients with previously treated advanced clear cell renal cell carcinoma.

David A. Braun, MD, PhD, of Yale School of Medicine

CheckMate-9ER Post-Hoc Analysis Seeks to Identify Efficacy Biomarkers for Nivolumab/Cabozantinib in RCC

Kristi Rosa
September 19th 2024
Article

Elevated fucosylation and sialylation of serum proteins were negative prognostic factors in RCC after treatment with nivolumab plus cabozantinib or sunitinib.

Renal Cell Carcinoma | Image Credit: © Crystal light - stock.adobe.com

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

Kyle Doherty
September 17th 2024
Article

Ipilimumab given in combination with nivolumab met the primary end point of 12-month OS rate vs SOC in patients with nccRCC in the SUNNIFORECAST trial.

Xinan Sheng, MD, of Peking University Cancer Hospital and Institute

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC

Kyle Doherty
September 17th 2024
Article

Benmelstobart plus anlotinib improved PFS, OS, and ORR vs sunitinib in first-line advanced renal cell carcinoma.

Toni Choueiri, MD, of Dana-Farber Cancer Institute

Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC

Megan Hollasch
September 13th 2024
Article

The addition of nivolumab to tivozanib did not improve outcomes in metastatic RCC and 1.34 mg of tivozanib monotherapy may be considered as a second-line therapy.

Brian Rini, MD

Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC

Caroline Seymour
September 13th 2024
Article

Belzutifan improved PFS and ORR but failed to deliver a significant improvement in OS vs everolimus in pretreated advanced clear cell renal cell carcinoma.